ER signaling is well known to be associated with the pathogenesis of breast cancer by demonstrating that excess production of estrogens due to enhanced aromatase activity or higher conversion rates of androgens to estrogens increases the risk for the development of breast and endometrium cancer [48]. This evidence concerns the gene CYP19A1 and endometrial cancer.